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Hepatic graft rejection is a common complication after
liver transplantation (LT), with a maximum incidence
within the first weeks. The identification of high-risk pa-
tients for early acute rejection (EAR) might be useful for
clinicians. A series of 133 liver graft recipients treated with
calcineurin inhibitors was retrospectively assessed to iden-
tify predisposing factors for EAR and develop a mathe-
matical model to predict the individual risk of each pa-
tient. The incidence of EAR (<45 days after LT) was
35.3%. Multivariate analysis showed that recipient age,
underlying liver disease, and Child’s class before LT were
independently associated with the development of EAR.
Combining these 3 variables, the following risk score for
the development of EAR was obtained: EAR score [F(x)] 5
2.44 1 (1.14 3 hepatitis C virus cirrhosis) 1 (2.78 3
immunologic cirrhosis) 1 (2.51 3 metabolic cirrhosis) 2
(0.08 3 recipient age in years) 1 (1.65 3 Child’s class).
Risk for rejection 5 eF(x)/1 1 eF(x). The combination of
age, cause of liver disease, and Child’s class may allow us
to predict the risk for EAR. (Liver Transpl 2001;7:
246-254.)
Acute rejection is a common complication after livertransplantation (LT), especially within the first
weeks after the procedure. Its incidence is variable,
ranging between 40% and 80% in different series.1-9
However, despite this greater incidence within the first
weeks after LT, acute rejection may appear several
months or even years after the procedure. Contrary to
early rejection episodes, these late episodes are consid-
ered to be the consequence of a lower degree of immu-
nosuppression.10
Different studies have aimed to identify patients
with a greater risk for developing acute rejection,2,3,11-17
but with some exceptions, they have been limited to a
small number of patients and focused on a limited
number of risk factors, and results are frequently con-
troversial. For this reason, there is no consensus about
the majority of factors predisposing to the appearance
of acute rejection after LT.
We studied a large number of potential parameters
predisposing to early acute rejection (EAR) after LT
and constructed a simple predicting rule that is easy to
apply to allow simple and rapid identification of these
high-risk patients.
Patients and Methods
Cohort Study
Patients undergoing LT at the Clinica Universitaria de Na-
varra (Pamplona, Spain) between April 1990 and April 1999
were retrospectively evaluated and selected for this study if
they fulfilled the following criteria: (1) adult (age . 18 years),
(2) primary LT, (3) immunosuppressive regimen based on
cyclosporine (CsA) or tacrolimus as the major immunosup-
pressant immediately after LT, and (4) patient or graft sur-
vival of 45 days or more after LT, or less in the case of an
episode of acute rejection within that time.
During this period, 15 patients were excluded from the
study for the following reasons: age younger than 18 years
(1 patient), patient or graft survival less than 7 days without
developing acute rejection (5 patients), and immunosuppres-
sion other than CsA or tacrolimus in the immediate postop-
erative period (9 patients). The final study group included
133 patients undergoing primary LT.
Immunosuppressive Treatment
All patients included on the study were treated with cal-
cineurin inhibitors; 83 patients, conventional CsA (Sandim-
mun; Novartis Pharma, Basilea, Switzerland); 32 patients,
CsA microemulsion (Neoral; Novartis Pharma); and 17 pa-
tients, tacrolimus (Prograf; Fujisawa Ireland Ltd, Killorglin,
Ireland) as the main immunosuppressant.
CsA group. The first 83 patients were administered intra-
venous CsA, which was subsequently switched to the oral
route. Intravenous CsA was administered as an intravenous
infusion at a dose of 2 mg/kg over 6 hours every 12 hours,
starting postoperative day 1. CsA levels were measured daily
by radioimmunoassay, and doses were adjusted to maintain
whole-blood concentrations between 250 and 300 ng/mL
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before the next CsA dose within the first 3 months after LT.
An intravenous bolus of 1,000 mg of methylprednisolone was
administered in the anhepatic phase of surgery. In the post-
operative period, steroid doses were tapered from 200 mg of
methylprednisolone day 1 to 20 mg of prednisone by day 6,
15 mg by day 180, 10 mg by day 365, 5 mg by the end of the
second year, and lower doses subsequently. Azathioprine was
administered at a dose of 1 to 2 mg/kg/d orally, starting when
the platelet count was less than 50,000/mL.
CsA microemulsion group. An initial dose of 5 mg/kg every
12 hours was administered as an oral solution through a
nasogastric tube within the first 6 hours after LT. Blood levels
were measured to achieve the same therapeutic levels de-
scribed for conventional CsA. Steroid doses during surgery
and within the first 30 days were the same described for CsA
and were tapered to 15 mg by day 30, 10 mg by day 90, 5 mg
by day 180, and finally discontinued at the end of the first
year. Azathioprine was administered with the same schedule
as that described for patients receiving conventional CsA.
Tacrolimus group. Tacrolimus was administered orally at
a dose of 0.05 mg/kg every 12 hours, starting within the first
6 hours after LT. Blood levels were measured by radioimmu-
noassay, and doses were adjusted to maintain levels of 10 to 12
ng/mL in the first 2 weeks, 9 to 11 ng/mL in weeks 3 and 4,
and 7 to 9 ng/mL in weeks 5 to 12. An initial dose of 5 mg/kg
of intravenous methylprednisolone was administered in the
intraoperative period and in the first postoperative day, fol-
lowed by a daily dose of 20 mg of prednisone orally within the
first month. Doses were subsequently tapered to 15 mg by day
30, 10 mg by day 90, 5 mg by day 120, and discontinued at
the end of the first year. Eleven patients also were adminis-
tered azathioprine, with the same schedule as that described
for patients administered conventional CsA.
Assessment of Acute Rejection
Diagnosis of acute rejection was based on clinical, biochemi-
cal, and histological criteria. In patients with clinical and
biochemical suspicion of acute rejection, a liver biopsy was
performed (unless contraindicated because of severe coagu-
lopathy) to obtain histological confirmation of rejection.
Liver biopsy was not performed in 2 episodes. In these 2
patients, the diagnosis of rejection was established because of
the presence of impaired liver function test results, with eo-
sinophilia and leukocytosis when other potential causes of
graft dysfunction had been ruled out. The diagnosis of rejec-
tion was retrospectively confirmed when liver function test
results and all other biochemical abnormal results returned to
normal values after treatment for acute rejection was initiated.
Histological criteria for acute rejection included the pres-
ence of: (1) mixed inflammatory but predominantly mono-
nuclear infiltrate in portal triads, with activated lymphocytes,
neutrophils, and frequently eosinophils; (2) subendothelial
inflammation of portal and/or terminal hepatic veins; and (3)
inflammation and/or damage of biliary epithelium. At least 2
of these 3 characteristics had to be present in the liver biopsy
specimen to establish the diagnosis of acute rejection.18 The
rejection activity index was obtained according to the recom-
mendations of the Third Banff Conference on Allograft Path-
ology.19
Definition of EAR
As stated before, acute rejection is especially frequent within
the first weeks after LT, decreasing thereafter. Several investi-
gators have established different definitions for EAR and late
acute rejection, and the limit between the 2 events has been
placed at 30 days,2,10 45 days,3 and 311 or 6 months20 after
LT. In our series, more than 90% of the episodes of acute
rejection developed within 45 days after transplantation; for
this reason, the barrier between early and late rejection was
defined as 45 days. We defined the day of appearance of EAR
as the post-LT day in which the impairment of liver function
test results that led to performing the diagnostic liver biopsy
was first detected.
Treatment of Acute Rejection
Acute rejection episodes were generally treated with the ad-
ministration of 1,000 mg of methylprednisolone daily for 3
consecutive days, followed by an oral recycle of prednisone.
Steroid-resistant acute rejection was treated with OKT3 (Or-
thoclone; Ortho-Biotech, Raritan, NJ). Some patients with
mild acute rejection episodes were treated with an increased
dosage of anticalcineurin drugs.
Statistical Analysis
Results are expressed as mean 6 SD and median and inter-
quartile range in the case of parametric or nonparametric
variables, respectively. Actuarial incidence of early graft rejec-
tion was estimated with the Kaplan-Meier21 method.
A stepwise logistic regression analysis was performed to
identify the group of variables independently associated with
the development of acute rejection within 45 days after LT.
Seventy-three preoperative, intraoperative, and postoperative
potential variables were considered to enter the model. Those
variables significant at P less than .2 in the univariate analysis
were subsequently included in the multivariate analysis, and a
stepwise selection model was used to identify the variables
independently associated with the appearance of EAR.
The potential variables introduced in the logistic regres-
sion analysis are listed next.
Preoperative factors. Recipient factors are age; sex; blood
group type A, type B, type O (ABO) and Rh; cause of liver
disease; Child’s class; liver function tests (aspartate transami-
nase, alanine transaminase, alkaline phosphatase, g-glutamyl
transpeptidase, total bilirubin) immediately before LT; serum
creatinine level immediately before LT; gammaglobulin lev-
els; immunoglobulin A, immunoglobulin G, and immuno-
globulin M levels; presence or absence of antinuclear antibod-
ies, antimitochondrial antibodies, smooth muscle antibodies,
or antibodies to liver/kidney microsome; history of blood
transfusions before LT; cytomegalovirus and Epstein-Barr vi-
rus serological status, panel reactive antigen status; presence of
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hepatocellular carcinoma; presence of autoimmune disease
before LT; positivity for the most frequent HLAs; days of
permanence in the waiting list; and in women, antecedent of
pregnancy or abortion before LT.
Donor factors include age, sex, cause of death, ABO blood
group and Rh, Epstein-Barr virus and cytomegalovirus sero-
logical status, hours in the intensive care unit, and presence or
absence of the more prevalent HLA antigens.
Donor-recipient interaction factors are sex match, ABO
group match, Rh match, cross-match, and HLA-I, HLA-II,
HLA-A, and HLA-B mismatches.
Intraoperative factors. These are arterial and portal isch-
emic times; number of units of red blood cells, fresh frozen
plasma, cryoprecipitate, and platelets administered during the
transplantation surgery; and intraoperative administration of
aprotinin and prostaglandin E1.
Postoperative factors. These are immunosuppressive regi-
men, moderate to severe preservation injury (defined as aspar-
tate transaminase level .600 U/L within the first 72 hours
after LT),22 and abdominal bleeding requiring a new laparot-
omy within 48 hours after LT.
To identify the individual risk for EAR for a given patient,
an equation was developed with those variables independently
associated with EAR, as follows:
F( x) 5 b0 1 b1x1 1 b2x2 1 · · · 1 b ixi
where x1, x2, . . . , xi are the significant prognostic factors and
b1, b2, and bi are the regression coefficients. Each regression
coefficient means that the effect of every prognostic factor is
multiplied by the value of the regression coefficient. The
greater the risk scores, the greater the probability of develop-
ing the event under study, in this case, the appearance of EAR.
After obtaining the equation formula, the predicted indi-
vidual risk could be calculated with the transformation:
R ( predicted probability of EAR) 5 eF( x)/1 1 eF( x)
Fit of the logistic model was assessed by the Hosmer-
Lemeshow goodness-of-fit test.23
The sensitivity and specificity of our predictive model was
estimated by means of a receiver operating characteristic
(ROC) curve.24 Statistical analysis was performed using the
Statistical Package for Social Sciences, version 9.0.1, (SPSS
Inc, Chicago, IL, 1999).
P less than .05 indicates statistical significance in all anal-
yses.
Results
Baseline characteristics of the cohort study population
are listed in Table 1.
Incidence of Acute Rejection
Among the 133 patients included on the study, 47
patients (35.3%) developed at least 1 episode of acute
rejection within 2 to 2,380 days after LT. Forty-three
patients (32.3%) developed 1 episode of acute rejec-
tion, and 4 patients (3%) developed a second episode.
Cumulative incidences of acute rejection at the end of
1, 3, and 5 years after LT were 33.9%, 33.9%, and
36.6%, respectively.
Forty-four of the 47 first episodes of acute rejection
(93.62%) were EAR (shown in Figure 1). The median
time of appearance of EAR after LT was 5 days (inter-
quartile range, 4 to 13 days). Rejection activity indices
Table 1. Characteristics of the 133 Patients Included
on the Study
No. %
Age (yr)* 55.28 6 9.76
Sex
Men 98 73.7
Women 35 26.3
Liver cirrhosis
No† 3 2.3
Yes 130 97.7
Indication for LT
Alcoholic cirrhosis 48 36.1
HCV cirrhosis 46 33.8
HBV cirrhosis 8 6
PBC, autoimmune CAH, adult
idiopathic ductopenia 9 8.8
Metabolic cirrhosis‡ 13 9.8
Miscellaneous§ 10 7.5
Hepatocellular carcinoma
No 91 68.4
Yes 42 31.6
Child’s class (n 5 130)
A 16 12.3
B 63 48.5
C 51 39.2
Recipient blood group
Group A 65 48.9
Group B 7 5.3
Group O 61 45.8
Recipient Rh
Negative 28 21.1
Positive 105 78.9
Days on the waiting list\ 82 (25-173)
Immunosuppressive regimen
CsA 83 62.4
CsA microemulsion 32 24.1
Tacrolimus 18 13.5
*Mean 6 SD.
†Familial amyloid polyneuropathy, 1 patient; polycystic liver
disease, 1 patient; epitheloid hemangioendothelioma, 1 pa-
tient.
‡Hemochromatosis, 8 patients; a1-antitrypsin deficiency, 3
patients; Wilson’s disease, 2 patients.
§Cryptogenic cirrhosis, 5 patients; Budd-Chiari syndrome, 2
patients; no cirrhosis, 3 patients.
\Median (interquartile range).
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of the EAR episodes were 2 (6 cases), 3 (8 cases), 4
(9 cases), 5 (11 cases), 6 (4 cases), 7 (2 cases), and 8
(1 case). In 3 cases, the rejection activity index was
not obtained because liver biopsy was not performed
(2 cases) or it was performed after the initiation of
treatment for rejection (1 case).
Only those patients with episodes of EAR were in-
cluded in the statistical analysis of predisposing factors.
Factors Associated With the Appearance
of EAR: Univariate Analysis
Only 7 variables showed an association with EAR with
a significance level less than .20 in univariate analysis.
They were cause of liver disease, recipient age, Child’s
class, number of cryoprecipitate units administered
during LT surgery, presence of preservation injury, and
route of administration of immunosuppressive treat-
ment in the immediate postoperative period (intrave-
nous CsA v CsA microemulsion or tacrolimus). Results
of univariate analysis are listed in Table 2.
Factors Independently Associated With EAR:
Multivariate Analysis
Three variables were independently associated with the
development of EAR in the multivariate logistic regres-
sion model: cause of liver disease, recipient age, and
Child’s class. The results of multivariate analysis are
shown in Figure 2 and Table 3.
The strongest association with the appearance of
Figure 1. Actuarial incidence of rejection within the first
45 days after LT (n 5 133).
Table 2. Parameters Potentially Associated With the Development of EAR by Univariate Analysis
Variable Incidence of EAR (%)
Unadjusted OR
(96% CI) P*
Cause of liver disease
Alcoholic cirrhosis 18.8 1
HCV cirrhosis 35.6 2.39 (0.93-6.17) .0714
HBV cirrhosis—others† 22.2 1.24 (0.33-4.66) .7524
Immune cirrhosis‡ 66.7 8.67 (1.81-41.41) .0068
Metabolic cirrhosis§ 69.2 9.75 (2.45-38.87) .0012
Recipient age (for every 1-year increase) 0.96 (0.92-0.94) .0247
Child’s class
B and C 30.7 1
A 56.3 2.90 (1.00-8.42) .0499
Cryoprecipitate (U administered during LT) 1.07 (1.00-1.14) .0312
AST immediately before LT (for every
1-U/L increase) 1.009 (0.99-1.02) .0859
Preservation injury
No or mild 28.4 1
Moderate to severe 48.4 2.36 (1.03-5.39) .0415
Route of immunosuppression
Oral (tacrolimus and CsA microemulsion) 26 1
Intravenous (CsA) 37.3 1.69 (0.78-3.67) .1799
Abbreviations: OR, odds ratio; CI, confidence interval; AST, aspartate aminotransferase.
*Wald test.
†Familial amyloid polyneuropathy, 1 patient; polycystic liver disease, 1 patient; epitheloid hemangioendothelioma, 1 patient; Budd-
Chiari syndrome, 2 patients; cryptogenic cirrhosis, 5 patients.
‡Autoimmune CAH, 2 patients; PBC, 6 patients; idiopathic adult ductopenia, 1 patient.
§Hemochromatosis, 8 patients; a1-antitrypsin deficiency, 3 patients; Wilson’s disease, 2 patients.
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EAR was an immunologically mediated underlying
liver disease.
In comparison with alcoholic liver cirrhosis (refer-
ence stratum), patients undergoing LT for metabolic
liver disease (hemochromatosis, Wilson’s disease, and
alpha1-antitrypsin deficiency) and hepatitis C virus
(HCV) cirrhosis had a significantly greater risk for
EAR.
Recipient age was also independently associated
with EAR: younger recipients were at greater risk. For
every 1-year increase in recipient age at the time of LT,
the risk for EAR decreased by 8%.
Finally, the functional reserve of liver transplant re-
cipients before LT was also independently associated
with EAR. Those patients in Child’s class A at the time
of LT had a risk for developing EAR 5 times greater
than those in Child’s classes B and C.
Calculation of the EAR Risk Score
After multivariate analysis, the regression coefficients
listed in Table 3 and the risk factors independently
associated with the presence of EAR were used to gen-
erate the following equation:
EAR score 5 2.44 1 (1.14 3 HCV-cirrhosis)
1 (2.78 3 PBC/autoimmune CAH
/idiopathic adulthood ductopenia)
1 (2.51 3 metabolic cirrhosis)
2 (0.08 3 recipient age in years)
1 (1.65 3 Child’s class),
where PBC is primary biliary cirrhosis and CAH is
Figure 2. Factors indepen-
dently associated with the de-
velopment of EAR after LT by
multivariate logistic regres-
sion analysis. *Reference
stratum, alcoholic cirrhosis.
**Reference stratum, Child’s
classes B and C.
Table 3. Variables Independently Associated With the Development of EAR by Multivariate Logistic Regression Analysis
Regression
Coefficient (b) SE (b) Adjusted OR 95% CI P *
Cause of liver disease
HCV cirrhosis 1.14 0.55 3.13 (1.07-9.15) .038
HBV cirrhosis—others 0.47 0.73 1.62 (0.38-6.78) .513
PBC, autoimmune CAH,
idiopathic adult ductopenia 2.78 0.86 16.07 (2.96-87.12) .001
Metabolic cirrhosis 2.51 0.77 12.34 (2.70-56.37) .001
Recipient age 20.08 0.03 0.92 (0.88-0.97) .003
Child’s class A 1.65 0.63 5.22 (1.51-18.03) .009
Constant 1.65 1.37
*Wald test.
Abbreviations: OR, odds ratio; CI, confidence interval.
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chronic active hepatitis. The different variables are
coded as follows: HCV cirrhosis (0 5 no, 1 5 yes),
PBC/autoimmune CAH/adult idiopathic ductope-
nia (0 5 no, 1 5 yes), metabolic cirrhosis (0 5 no,
1 5 yes), and Child’s class (0 5 Child’s class B or C,
1 5 Child’s class A).
For example, for a hypothetical patient aged 26 years
who underwent LT for autoimmune CAH and with
good hepatocellular function (Child’s class A), the score
for acute rejection would be:
EAR 5 2.44 1 (1.14 3 0) 1 (2.78 3 1)
1 (2.51 3 0) 2 (0.08 3 26) 1 (1.65 3 1)
5 4.79
The predicted risk for EAR for this patient would be:
EAR risk 5 e4.79/1 1 e4.79 5 0.827
which means this patient has a probability of 82.7% of
developing an episode of acute rejection within 45 days
after LT.
The Hosmer-Lemeshow goodness-of-fit test (Chi-
squared 5 5.27; df 5 8; P 5 .728) showed that the
constructed multivariate model supported the data
well. Finally, the regression model was completed, with
the construction of an ROC curve (Fig. 3). The calcu-
lation of the area under the curve (0.77) indicated an
acceptable discriminative ability of our model. With the
combination of these prognostic factors, our model was
able to classify correctly 77% of patients who will expe-
rience EAR after LT.
Discussion
Acute rejection is a frequent complication after LT,
with an incidence ranging between 40% and 80% in
different series.1-9 In most series, such as ours, most
episodes of graft rejection developed in the first weeks
after LT, leading to a distinction between early and late
graft rejection. Late graft rejection is frequently the
consequence of a reduction in immunosuppressive
therapy,10 its response to immunosuppression is
worse,2 and it poses a greater risk for progression to
chronic rejection.10
Conversely, EAR develops in a certain population of
patients despite adequate immunosuppression, and in
most cases, it responds to treatment.2 However, this
must not lead to an underestimation of its importance
because treatment of the rejection is associated with a
number of side effects, such as an increased risk for
infections,25 recurrence of hepatitis C in patients who
underwent transplantation for HCV cirrhosis,26 and
such metabolic complications as diabetes mellitus, hy-
perlipidemia, or hypertension.27
In our series, EAR appeared in 35.3% of the trans-
plant recipients, with a median time of 5 days. This
incidence is similar to that of some series6,12,28,29 and
clearly less than that of others.2,11,30 These different
incidences may be caused mainly by the diagnostic cri-
teria of acute rejection. As an example, those centers
that perform protocol biopsies at the end of the first
week after LT reported a greater incidence of acute
rejection than centers performing liver biopsy only
when clinically indicated.31
Because acute rejection does not uniformly develop
in all patients after LT, one could speculate that iden-
tification of these patients with a greater risk for rejec-
tion could be useful to modify the immunosuppressive
regimen. In this report, we propose an easy way to
identify these high-risk patients, using a score that may
predict the individual risk of a given patient.
The only 3 factors independently associated with
EAR in our series were recipient age, Child’s class im-
mediately before LT, and cause of the indication for
LT. Therefore, younger patients, those with better hep-
atocellular liver function (Child’s class A), and those
who underwent transplantation for liver diseases other
than alcoholic cirrhosis had a greater risk for EAR.
Several3,11 but not all studies12,13 have shown an
Figure 3. ROC curve for the logistic regression model
using recipient age, cause of liver disease, and Child’s class
as independent predictors of EAR. Sensibility (true-posi-
tive fraction) and 1-specificity (false-positive fraction) are
computed for each possible value of the predicted model.
The area under the ROC curve is 0.77.
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inverse association between recipient age and incidence
of acute rejection. This association has also been de-
scribed for kidney transplant recipients.32 This link
may reflect the immunologic changes that appear
with aging; namely, the reduction in total lymphocyte
count; change in lymphocyte subsets, with a switch
from T helper subtype 1 to T helper subtype 2 predom-
inance; and a decreased response to antigenic stimu-
li.33,34 All these changes lead to a decrease in both in-
terleukin-2 and interferon-g synthesis.35,36 The final
result is a debilitated response of the immune system.
The risk for EAR was also different depending on
the cause of liver disease in the recipient. Overall, pa-
tients with a lower risk for EAR were those who under-
went transplantation for hepatitis B virus (HBV) cir-
rhosis and alcoholic cirrhosis.
In comparison to patients with alcoholic cirrhosis,
those who underwent transplantation for HCV cirrho-
sis, metabolic cirrhosis, and immunologically mediated
cirrhosis had risks 3, 12, and 16 times greater for devel-
oping EAR, respectively.
The lower incidence of EAR in patients with alco-
holic cirrhosis added to a greater prevalence of bacterial
infection after LT in some series12 suggests an immu-
nologic disturbance responsible for these 2 abnormali-
ties. The immunosuppressive effects derived from alco-
hol consumption persist for several weeks or even
months after alcohol withdrawal,37,38 which might ex-
plain the reduced incidence of EAR in patients with
alcoholic cirrhosis and the lack of difference in the
incidence of chronic rejection compared with other
causes.12 However, the potential effect of alcohol con-
sumption in our patients should be negligible because
most of our transplant recipients had not consumed
alcohol in the 6 months immediately before LT and
remained abstinent in the postoperative period.
The greater incidence of EAR in patients who un-
derwent transplantation for HCV cirrhosis compared
with patients with alcoholic cirrhosis might be ex-
plained by the misdiagnosis of EAR instead of hepatitis
C. Both entities may have common histopathologic
features.39 In our series, the differential diagnosis be-
tween both entities was not only based on histopatho-
logic features (including rereview of liver biopsy speci-
mens), but also on evolution after treatment and time of
appearance. In this series, two thirds of the EAR epi-
sodes developed in the first 2 weeks after LT, a period in
which hepatitis C recurrence is very uncommon.
One important aspect to consider is that none of the
patients with HBV cirrhosis developed EAR during
follow-up. This finding has been previously described
by others12,14,15 and may be a reflection of the deranged
immune system in patients chronically infected by
HBV. Additionally, hyperimmune immunoglobulin
prophylactically administered to these patients to avoid
graft reinfection also could have contributed to the de-
creased incidence of EAR because of its immunosup-
pressive properties.12
However, although they had the lowest incidence of
EAR, the absence of events (EAR) in this reduced num-
ber of patients who underwent LT for HBV cirrhosis
(8 patients) did not allow its independent introduction
in the multivariate analysis as a potential predictive
value. For this reason, this group of patients was com-
bined with a group of patients undergoing LT for dif-
ferent reasons (2 patients, Budd-Chiari syndrome; 5
patients, cryptogenic cirrhosis; and 3 patients, diseases
other than hepatic cirrhosis).
The strongest association with EAR in our series was
immunologically mediated liver disease as the indica-
tion for LT. Compared with the patients who under-
went LT for alcoholic cirrhosis, those who underwent
LT for PBC, autoimmune CAH, or adulthood idio-
pathic ductopenia had a risk 16 times greater for EAR.
This increased incidence of acute rejection had been
previously described13,16 and may reflect the persistence
of a hyperactive immune system in these patients, prone
to react with self and nonself antigens.
Those patients undergoing LT for metabolic cirrho-
sis also showed an increased risk for EAR. Compared
with patients with alcoholic cirrhosis, those who under-
went LT for metabolic cirrhosis showed a 12-fold in-
creased risk for EAR. This greater incidence of EAR in
these patients has not been described before. Con-
versely, in other series, patients who underwent LT for
metabolic cirrhosis had an intermediate risk for acute
rejection compared with other causes.3 There is no clear
explanation for this finding. Considering the heteroge-
neity of this group of patients, it is possible there is an
unidentified underlying factor shared by these 3 causes
and responsible for this greater incidence of rejection.
In any case, additional prospective analysis of 3 causes
separately would help clarify this finding.
Finally, the third factor independently associated
with EAR was hepatocellular function of the liver trans-
plant recipients. Those patients with good liver func-
tion, namely, patients in Child’s class A, had a risk for
EAR 5 times greater than those in Child’s class B or C.
The influence of functional hepatic reserve on the
development of EAR has not been previously reported
as an independent risk factor. The link between hepatic
function and acute rejection may be related to the im-
munologic disturbances described in patients with liver
cirrhosis. An additional immunosuppressive factor may
252 Go´mez-Manero et al
be the coexistence of malnutrition in advanced cirrho-
sis. Protein-calorie malnutrition is a common finding in
patients with cirrhosis, related more to the severity than
to the cause of liver disease.40 Because malnutrition is
considered the most prevalent acquired immunodefi-
ciency,41 it is reasonable to think that those patients
with worse hepatocellular function would be more se-
verely malnourished, and subsequently more immuno-
suppressed, explaining the reduced incidence of EAR
when liver function fails. In accordance with this idea, a
recent report showed a reduced incidence of acute re-
jection in malnourished patients compared with pa-
tients with a better nutritional state.17
In summary, acute rejection is a common complica-
tion within the first 45 days after LT. However, the risk
for EAR appears to be different among transplant recip-
ients. Younger patients, those who undergo LT for liver
diseases other than alcoholic cirrhosis, and those with
better hepatocellular function are at greater risk. We
propose a mathematical model to help clinicians iden-
tify those patients at high risk by combining 3 simple
parameters related to patient characteristics.
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254 Go´mez-Manero et al
Erratum
In the article by Go´mez-Manero et al entitled “Prognostic Model for Early Acute Rejection After Liver Trans-
plantation,” which appeared in the March 2001 issue (Vol 7, No 3, pp 246-254), the following corrections should
be noted. On page 246, the sentence beginning on line 13 of the abstract should read as follows: “Combining these
3 variables, the following risk score for the development of EAR was obtained: EAR score [F(x)] 2.44 (1.14
hepatitis C virus cirrhosis) (2.78 immunologic cirrhosis) (2.51metabolic cirrhosis) (0.08 recipient
age in years) (1.65Child’s class A).” On page 250, in Table 3, the value for the Constant Regression Coefficient
() should be listed as 2.44. On page 251, the sentence beginning on line 14 of the first column should read as
follows: “The predicted risk for EAR for this patient would be:
EAR risk  e4.791  e4.79  0.99
which means this patient has a probability of 99% of developing an episode of acute rejection within 45 days
after LT.”
